Copyright
©The Author(s) 2016.
World J Meta-Anal. Oct 26, 2016; 4(5): 105-117
Published online Oct 26, 2016. doi: 10.13105/wjma.v4.i5.105
Published online Oct 26, 2016. doi: 10.13105/wjma.v4.i5.105
Table 2 Patient demographics and disease characteristics
| Ref. | Patients (n) | Age(median) | Male: Female | Primary tumor | Primary tumor treatmentn (%) | Liver involvement n (%) or mean percentage (range) | Number of liver metastases | Largest liver metastases diameter (cm), median (range) | Extra-hepatic metastases n (%) | ||||
| Excision | Chemotherapy | No treatment | < 5% | 25%-0% | > 0% | ||||||||
| Olofsson et al[55] | 34 | 61 (17-77) | 15:19 | Ocular melanoma | 15 (44%) | 19 (56%) | None | 31 (91%) | 3 (9%) | None | 1-100 31 (91%) > 100 3(9%)) | 2.35 (1.0-6.4) | None |
| Magge et al[56] | 91 | 54.3 (24-77) | 50:41 | CRC 54 (59.3%) Ocular melanoma 29 (32%) Others 8 (8.7%) | None | CRC 47 (87%) | 44 (48%) | 30% (5%-80%) | 9 (2-105) | NR | NR | ||
| Fukumoto et al[57] | 68 | 60 (52-67) | 61:7 | HCC | 68 (100%) | NR | None | NR | NR | NR | ≥ 4 | 8.3 (5.0-12.6) | None |
| Alexander et al[58] | 120 | 52 (22-74) | 41:79 | CRC | NR | NR | NR | 20% (5%-75%) | NR | 8 (1-50) | NR | ||
| Iersel et al[59] | 105 | ≤ 70 | 78:27 | CRC | 4 (3.8%) | 51 (48.6%) | 50 (47.6%) | NR | NR | NR | < 10 71 (68%) ≥ 10 34 (32%) | NR | 34 (32.4%) |
| Rizell et al[60] | 27 | 53 (36-77) | NR | Melanoma | NR | NR | NR | 6 (22%) | 11 (41%) | 10 (37%) | NR | NR | NR |
| Pingpank et al[61] | 28 | 49 (17-74) | 14:14 | Melanoma 13 CRC 2 Others 13 | NR | NR | NR | NR | NR | NR | NR | NR | 8 (29%) |
| Alexander et al[62] | 29 | 49 (26-73) | 15:14 | Ocular melanoma | NR | NR | NR | 20 (69%) | 8 (28%) | 1 (3%) | 25 (4 ≥ 50) | 5.6 (2-14) | NR |
- Citation: Meng T, Li GQ, Dai MH. Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis. World J Meta-Anal 2016; 4(5): 105-117
- URL: https://www.wjgnet.com/2308-3840/full/v4/i5/105.htm
- DOI: https://dx.doi.org/10.13105/wjma.v4.i5.105